Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain

Pain Physician

Volumn 16, Issue 3, 2013, Pages

  Biondi, David ^a   Xiang, Jim ^a   Benson, Carmela ^a   Etropolski, Mila ^a   Moskovitz, Bruce ^a   Rauschkolb, Christine ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acute low back pain; Flexible dosing; Gastrointestinal tolerability; Neuropathic pain; Oxycodone; Radicular leg pain; Radiculopathy; Tapentadol

Indexed keywords

OXYCODONE; TAPENTADOL;

ADULT; AGED; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEG PAIN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PAIN ASSESSMENT; PARALLEL DESIGN; PATIENT SATISFACTION; PRURITUS; RADICULAR PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN DISEASE; SOMNOLENCE; UNITED STATES; VOMITING;

ACUTE PAIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; OUTPATIENTS; OXYCODONE; PAIN MEASUREMENT; PHENOLS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84878261372     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Palangio M, Morris E, Doyle RT, Jr., Dornseif BE, Valente TJ. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. Clin Ther 2002; 24:87-99.
2. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine (Phila Pa 1976) 1995; 20:11-19.
3. Freburger JK, Holmes GM, Agans RP, Jackman AM, Darter JD, Wallace AS, Castel LD, Kalsbeek WD, Carey TS. The rising prevalence of chronic low back pain. Arch Intern Med 2009; 169:251-258.
4. Rubin DI. Epidemiology and risk factors for spine pain. Neurol Clin 2007; 25:353-371.
5. Levin JH, Smuck MW. Radiculopathy from herniation of the nucleus pulposus:1. Epidemiology, pathophysiology, and natural history. J Back Musculoskel Rehabil 2007; 20:97-101.
6. Tarulli AW, Raynor EM. Lumbosacral radiculopathy. Neurol Clin 2007; 25:387-405.
7. Devereaux M. Low back pain. Med Clin North Am 2009; 93:477-501.
8. Visco CJ, Cheng DS, Kennedy DJ. Pharmaceutical therapy for radiculopathy. Phys Med Rehabil Clin N Am 2011; 22:127-137.
9. Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: A systematic review. J Pain 2002; 3:159-180.
10. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic nonmalignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7:R1046-R1051.
11. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003; 74:102-112.
12. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies H-H, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broadspectrum analgesic properties. J Pharmacol Exp Ther 2007; 323:265-276.
13. Daniels S, Casson E, Stegmann JU, Oh C, Okamoto A, Rauschkolb C, Upmalis D. A randomized, double-blind, placebocontrolled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009; 25:1551-1561.
14. Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009; 25:765-776.
15. Hartrick C, Van Hove I, Stegmann J-U, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, doubleblind, active-and placebo-controlled study. Clin Ther 2009; 31:260-271.
16. Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther 2011; 28:401-417.
17. Atlas SJ, Deyo RA, Parick DL, Convery K, Keller RB, Singer DE. The Quebec Task Force classification for Spinal Disorders and the severity, treatment, and outcomes of sciatica and lumbar spinal stenosis. Spine (Phila Pa 1976) 1996; 21:2885-2892.
18. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, Mc-Cormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113:9-19.
19. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA, Melzack R. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009; 144:35-42.
20. Nucynta® (tapentadol) immediaterelease oral tablets [package insert]. Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ, 2011.